Glycomimetics are drugs that mimic glycan structures. Among them, the development of selectin antagonists is being significantly advanced. For example, a pan-selectin inhibitor, Rivipansel, has been approved by the Food and Drug Administration (FDA) for vascular occlusion in sickle cell anemia. Currently, the development of various glycomimetics against various lectins such as the galectin and siglec family, as well as glycomimetics that inhibit E-selectin alone or both E-selectin and a chemokine receptor is being advanced.